ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

China approves first domestic COVID vaccine, developed by Sinopharm

Company says efficacy rate is 79%, paving way for large-scale inoculations

SHANGHAI -- China approved the country's first domestically made COVID-19 vaccine on Thursday, paving the way for mass inoculation and recognition overseas.

Developed by the Beijing Biological Products Institute under China National Pharmaceutical Group, or Sinopharm, the vaccine showed 79.34% efficacy and a 99.52% antibody positive conversion rate in Phase 3 clinical trial results, the institute announced a day earlier.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more